ROBERT M HERSHBERG, MD PHD
Medical Practice at Pacific St, Seattle, WA
License number
Washington MD00031962
Category
Medical Practice
Type
Clinical Genetics (M.D.)
Address
Address
1959 NE Pacific St, Seattle, WA 98195
Phone
(206) 616-2135
(206) 543-6420
(206) 543-6420
Personal information
See more information about ROBERT M HERSHBERG at radaris.comName
Address
Phone
2809 10Th Ave E, Seattle, WA 98102
6028 Eagle Harbor Dr NE, Bainbridge Island, WA 98110
2221 22Nd Ave E, Seattle, WA 98112
1523 Grand Ave, Seattle, WA 98122
6028 Eagle Harbor Dr NE, Bainbridge Island, WA 98110
Professional information
See more information about ROBERT M HERSHBERG at trustoria.com
Robert Mark Hershberg, Seattle WA
Robert Mark Hershberg, Seattle WA
Specialties:
Medical Genetics, Clinical Genetics, M.D., Surgery, Geriatric Medicine
Work:
UW Medical Center Genetics Clinic
1959 Ne Pacific St, Seattle, WA 98195
1959 Ne Pacific St, Seattle, WA 98195
Education:
University of California at Los Angeles (1992)
Toll-Like Receptor Agonist Formulations And Their Use
Toll-Like Receptor Agonist Formulations And Their Use
US Patent:
2013001, Jan 17, 2013
Filed:
Jul 16, 2012
Appl. No.:
13/550192
Inventors:
J. Jeffry Howbert - Redmond WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US
International Classification:
A61K 31/55, A61P 31/00, A61P 17/00, A61P 35/00
US Classification:
51421701
Abstract:
The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
Toll-Like Receptor Agonist Formulations And Their Use
Toll-Like Receptor Agonist Formulations And Their Use
US Patent:
8242106, Aug 14, 2012
Filed:
Jul 31, 2009
Appl. No.:
12/533596
Inventors:
J. Jeffry Howbert - Bellevue WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US
Assignee:
VentiRx Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 31/55, C07D 223/16
US Classification:
51421301, 540593
Abstract:
The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
Therapeutic Use Of A Tlr Agonist And Combination Therapy
Therapeutic Use Of A Tlr Agonist And Combination Therapy
US Patent:
2012021, Aug 30, 2012
Filed:
Oct 3, 2011
Appl. No.:
13/252147
Inventors:
Robert Hershberg - Seattle WA, US
George Coukos - Wynnewood PA, US
Gregory Dietsch - Snohomish WA, US
Andrea Facciabene - Philadelphia PA, US
Kristi Manjarrez - Seattle WA, US
Tressa D. Randall - Mukilteo WA, US
George Coukos - Wynnewood PA, US
Gregory Dietsch - Snohomish WA, US
Andrea Facciabene - Philadelphia PA, US
Kristi Manjarrez - Seattle WA, US
Tressa D. Randall - Mukilteo WA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
VentiRx Pharmaceuticals, Inc. - Seattle WA
VentiRx Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 31/55, A61K 31/7068, A61K 31/664, A61N 5/00, A61K 9/127, A61K 39/395, A61K 38/22, A61K 38/19, A61K 31/704, A61P 35/00
US Classification:
424450, 51421301, 514 34, 514 49, 514110, 4241301, 514 97, 514 76, 600 1
Abstract:
The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.
Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity
Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity
US Patent:
2012000, Jan 5, 2012
Filed:
Apr 21, 2011
Appl. No.:
13/092088
Inventors:
Robert Hershberg - Seattle WA, US
International Classification:
A61K 39/395, C07D 403/10, A61P 29/00, A61P 35/00, A61P 35/02
US Classification:
4241331, 4241411, 4241381, 4241531, 540593
Abstract:
The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
Substituted Benzoazepines As Toll-Like Receptor Modulators
Substituted Benzoazepines As Toll-Like Receptor Modulators
US Patent:
2011009, Apr 21, 2011
Filed:
Aug 18, 2010
Appl. No.:
12/859178
Inventors:
James Jeffry Howbert - Redmond WA, US
Gregory Dietsch - Snohomish WA, US
Robert Hershberg - Seattle WA, US
Laurence E. Burgess - Boulder CO, US
Joseph P. Lyssikatos - Piedmont CA, US
Brad Newhouse - Boulder CO, US
Hong Woon Yang - Boulder CO, US
Gregory Dietsch - Snohomish WA, US
Robert Hershberg - Seattle WA, US
Laurence E. Burgess - Boulder CO, US
Joseph P. Lyssikatos - Piedmont CA, US
Brad Newhouse - Boulder CO, US
Hong Woon Yang - Boulder CO, US
Assignee:
VentiRx Pharmaceuticals, Inc. - San Diego CA
Array BioPharma, Inc. - Boulder CO
Array BioPharma, Inc. - Boulder CO
International Classification:
A61K 31/55, C07D 223/16, A61P 11/06, A61P 37/02, A61P 35/00
US Classification:
51421301, 540593
Abstract:
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Compositions And Methods For The Therapy And Diagnosis Of Inflammatory Bowel Disease
Compositions And Methods For The Therapy And Diagnosis Of Inflammatory Bowel Disease
US Patent:
2009014, Jun 4, 2009
Filed:
Feb 25, 2008
Appl. No.:
12/036588
Inventors:
Robert M. Hershberg - Seattle WA, US
Nancy Ann Hosken - Seattle WA, US
Michael J. Lodes - Seattle WA, US
Raodoh Mohamath - Seattle WA, US
Stephan R. Targan - Santa Monica CA, US
Nancy Ann Hosken - Seattle WA, US
Michael J. Lodes - Seattle WA, US
Raodoh Mohamath - Seattle WA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
Corixa Corporation - Seattle WA
International Classification:
G01N 33/53
US Classification:
435 721, 436501, 435 79
Abstract:
Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
Methods For The Treatment Of Allergic Diseases
Methods For The Treatment Of Allergic Diseases
US Patent:
2012008, Apr 5, 2012
Filed:
Oct 3, 2011
Appl. No.:
13/252146
Inventors:
Robert Hershberg - Seattle WA, US
Assignee:
VentiRx Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 31/55, A61P 17/00, A61P 11/06, A61K 48/00, A61K 39/395, A61K 31/56, A61K 38/22, A61K 38/19, A61P 37/08, A61P 11/02
US Classification:
4241301, 51421301, 514171, 514 97, 514 76, 514 44 R
Abstract:
The present invention is directed generally to a TLR8 agonist VTX-378, for use in the treatment or prevention of allergic diseases, including allergic rhinitis.
Regeneration Of Chromatography Material
Regeneration Of Chromatography Material
US Patent:
6972327, Dec 6, 2005
Filed:
May 8, 2002
Appl. No.:
10/143594
Inventors:
Hassan Madani - Seattle WA, US
Robert D. Hershberg - Bainbridge Island WA, US
Robert D. Hershberg - Bainbridge Island WA, US
Assignee:
Immunex Corporation - Seattle WA
International Classification:
C07K001/22
US Classification:
530413, 210670, 436824, 436828
Abstract:
The invention provides improved methods of regenerating and using affinity chromatography material, in particular Protein A affinity chromatography resins.
Pres At Robert Hershberg Inc
Pres At Robert Hershberg Inc
Position:
Pres at Robert Hershberg Inc
Location:
Greater Seattle Area
Industry:
Pharmaceuticals
Work:
Robert Hershberg Inc
-
Pres